ATE392219T1 - Methoden und medizinische zusammensetzungen zur intravesikalen behandlung von blasenkrebs - Google Patents
Methoden und medizinische zusammensetzungen zur intravesikalen behandlung von blasenkrebsInfo
- Publication number
- ATE392219T1 ATE392219T1 AT03738247T AT03738247T ATE392219T1 AT E392219 T1 ATE392219 T1 AT E392219T1 AT 03738247 T AT03738247 T AT 03738247T AT 03738247 T AT03738247 T AT 03738247T AT E392219 T1 ATE392219 T1 AT E392219T1
- Authority
- AT
- Austria
- Prior art keywords
- bladder cancer
- methods
- medical compositions
- multispecific antibody
- intravesical treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
- A61K47/6897—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/66—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
- A61K47/665—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells the pre-targeting system, clearing therapy or rescue therapy involving biotin-(strept) avidin systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1084—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being a hybrid immunoglobulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1084—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being a hybrid immunoglobulin
- A61K51/109—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being a hybrid immunoglobulin immunoglobulins having two or more different antigen-binding sites or multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Nanotechnology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Reproductive Health (AREA)
- Crystallography & Structural Chemistry (AREA)
- Gynecology & Obstetrics (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US38439102P | 2002-06-03 | 2002-06-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE392219T1 true ATE392219T1 (de) | 2008-05-15 |
Family
ID=29712024
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT03738247T ATE392219T1 (de) | 2002-06-03 | 2003-06-02 | Methoden und medizinische zusammensetzungen zur intravesikalen behandlung von blasenkrebs |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20040022726A1 (de) |
| EP (1) | EP1509255B1 (de) |
| JP (1) | JP2006501157A (de) |
| AT (1) | ATE392219T1 (de) |
| AU (1) | AU2003244762A1 (de) |
| CA (1) | CA2488269A1 (de) |
| DE (1) | DE60320398T2 (de) |
| WO (1) | WO2003101496A1 (de) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7405320B2 (en) | 1998-06-22 | 2008-07-29 | Immunomedics, Inc. | Therapeutic and diagnostic conjugates for use with multispecific antibodies |
| US20040067235A1 (en) * | 2002-07-29 | 2004-04-08 | Rajiv Doshi | Methods for the use of neurotoxin in the treatment of urologic disorders |
| HUE033533T2 (en) | 2003-04-30 | 2017-12-28 | Universität Zuerich | A method of treating cancer using immunotoxin |
| JP4937751B2 (ja) * | 2003-06-13 | 2012-05-23 | イミューノメディクス、インコーポレイテッド | Ｄ−アミノ酸ペプチド |
| US20050152842A1 (en) * | 2003-12-24 | 2005-07-14 | Chun Li | Poly (L-glutamic acid) paramagnetic material complex and use as a biodegradable MRI contrast agent |
| US8361490B2 (en) * | 2004-09-16 | 2013-01-29 | Theracoat Ltd. | Biocompatible drug delivery apparatus and methods |
| WO2006097682A1 (en) * | 2005-03-18 | 2006-09-21 | Ucl Business Plc | Mechano growth factor peptides and their use |
| CL2008001071A1 (es) * | 2007-04-17 | 2009-05-22 | Smithkline Beecham Corp | Metodo para obtener anticuerpo penta-especifico contra il-8/cxcl8, gro-alfa/cxcl1, gro-beta/cxcl2), gro-gama/cxcl3 y ena-78/cxcl5 humanas; anticuerpo penta-especifico; proceso de produccion del mismo; vector, hbridoma o celela que lo comprende; composicion farmceutica; uso para tratar copd, otras enfermedades. |
| JP2008297203A (ja) * | 2007-05-29 | 2008-12-11 | Chisso Corp | 複合体 |
| JP5224531B2 (ja) * | 2009-02-09 | 2013-07-03 | Ｔｏｔｏ株式会社 | 膀胱癌治療剤 |
| CA2768658C (en) * | 2009-07-22 | 2018-04-03 | Actinium Pharmaceuticals, Inc. | Methods for generating radioimmunoconjugates |
| WO2015048901A1 (en) | 2013-10-02 | 2015-04-09 | Viventia Bio Inc. | Anti-epcam antibodies and methods of use |
| US10583198B2 (en) | 2015-03-12 | 2020-03-10 | Viventia Bio Inc. | Dosing strategies for targeting EPCAM positive bladder cancer |
| CN108513547A (zh) | 2015-03-12 | 2018-09-07 | 维文蒂亚生物公司 | 用于epcam阳性膀胱癌的治疗方法 |
| JP2022504648A (ja) * | 2018-10-10 | 2022-01-13 | ユニヴァーシティ オブ ワシントン | 高ポリマー密度バイオコンジュゲート組成物及び関連方法 |
| CN115089728B (zh) * | 2022-06-16 | 2024-01-26 | 磐如生物科技(天津)有限公司 | 一种膀胱癌靶向纳米药物及其制备方法 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4444744A (en) * | 1980-03-03 | 1984-04-24 | Goldenberg Milton David | Tumor localization and therapy with labeled antibodies to cell surface antigens |
| US5019368A (en) * | 1989-02-23 | 1991-05-28 | Cancer Biologics, Inc. | Detection of necrotic malignant tissue and associated therapy |
| US5612016A (en) * | 1988-04-01 | 1997-03-18 | Immunomedics, Inc. | Conjugates of antibodies and bifunctional ligands |
| US5965132A (en) * | 1992-03-05 | 1999-10-12 | Board Of Regents, The University Of Texas System | Methods and compositions for targeting the vasculature of solid tumors |
| PT627940E (pt) * | 1992-03-05 | 2003-07-31 | Univ Texas | Utilizacao de imunoconjugados para o diagnostico e/ou terapia de tumores vascularizados |
| DE69738353T2 (de) * | 1996-07-12 | 2009-09-24 | Immunomedics, Inc. | Radiometall-bindende peptide analoge |
| AU760854B2 (en) * | 1998-06-22 | 2003-05-22 | Immunomedics Inc. | Use of bi-specific antibodies for pre-targeting diagnosis and therapy |
| US6962702B2 (en) * | 1998-06-22 | 2005-11-08 | Immunomedics Inc. | Production and use of novel peptide-based agents for use with bi-specific antibodies |
| NZ514918A (en) * | 1999-04-28 | 2003-11-28 | Univ Texas | Compositions and methods for cancer treatment by selectively inhibiting VEGF |
| FR2816620B1 (fr) * | 2000-11-16 | 2003-02-21 | Inst Nat Sante Rech Med | Nouveaux composes pour des applications a la radioimmunoscintingraphie et/ou a la radioimmunotherapie des cancers |
| JP2005501052A (ja) * | 2001-07-31 | 2005-01-13 | イムノメディクス， インコーポレイテッド | ポリマー送達系 |
| PL372144A1 (en) * | 2001-12-26 | 2005-07-11 | Immunomedics, Inc. | Methods of generating multispecific, multivalent agents from v sb h /sb and v sb l /sb domains |
| US7011816B2 (en) * | 2001-12-26 | 2006-03-14 | Immunomedics, Inc. | Labeling targeting agents with gallium-68 and gallium-67 |
-
2003
- 2003-05-30 US US10/448,327 patent/US20040022726A1/en not_active Abandoned
- 2003-06-02 JP JP2004508850A patent/JP2006501157A/ja active Pending
- 2003-06-02 AT AT03738247T patent/ATE392219T1/de not_active IP Right Cessation
- 2003-06-02 DE DE60320398T patent/DE60320398T2/de not_active Expired - Lifetime
- 2003-06-02 EP EP03738247A patent/EP1509255B1/de not_active Expired - Lifetime
- 2003-06-02 AU AU2003244762A patent/AU2003244762A1/en not_active Abandoned
- 2003-06-02 CA CA002488269A patent/CA2488269A1/en not_active Abandoned
- 2003-06-02 WO PCT/GB2003/002387 patent/WO2003101496A1/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| EP1509255B1 (de) | 2008-04-16 |
| JP2006501157A (ja) | 2006-01-12 |
| WO2003101496A1 (en) | 2003-12-11 |
| CA2488269A1 (en) | 2003-12-11 |
| AU2003244762A1 (en) | 2003-12-19 |
| DE60320398D1 (de) | 2008-05-29 |
| US20040022726A1 (en) | 2004-02-05 |
| EP1509255A1 (de) | 2005-03-02 |
| DE60320398T2 (de) | 2009-05-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE392219T1 (de) | Methoden und medizinische zusammensetzungen zur intravesikalen behandlung von blasenkrebs | |
| BRPI0418745A (pt) | anticorpo linhagem de células, composição farmacêutica, e, método de tratamento de cáncer em um paciente | |
| CY1109817T1 (el) | Ολιγο-βητα-(1,3)-γλυκανη και μονοκλωνικα αντισωματα εναντιον καρκινου | |
| DE60316779D1 (de) | Thiadiazolylpiperazinderivate geeignet für die behandlung bzw. prävention von schmerzen | |
| DK2484365T3 (da) | Sammensætninger og fremgangsmåde til behandling af neovaskulære sygdomme | |
| DK1346041T3 (da) | Terapeutiske midler og fremgangsmåder til anvendelse deraf til behandling af en amyloidogen sygdom | |
| NO20074999L (no) | Metode og preparat for behandling av perifere vaskulaere sykdommer | |
| ATE330631T1 (de) | Antikörperfragmente zur lokalen behandlung von augenerkrankungen | |
| LU91928I2 (fr) | Ipilimumab et ses dérivés pharmaceutiquement acceptables (YERVOY®) | |
| CY1108765T1 (el) | ΑΓΩΓΗ ME ΑΝΤΙΣΩΜΑΤΑ ANTI-ErbB2 | |
| EA200970335A1 (ru) | Композиции и способы для диагностики и лечения рака | |
| EA200501319A1 (ru) | Способы лечения боли введением антагониста фактора роста нервов и нестероидного противовоспалительного средства и содержащие их композиции | |
| NO20054494L (no) | Peptidvektorer | |
| ATE355288T1 (de) | Verbindungen und therapeutische methoden | |
| EA202190403A1 (ru) | Лечение метастатической опухоли головного мозга путем введения конъюгата антитело-лекарственное средство | |
| NO20060912L (no) | Preoperativ behandling for postoperativ smerte | |
| NO20055390L (no) | Thorium-227 for anvendelse i radioterapi pa mykvevssykdommer | |
| ATE297751T1 (de) | Kombinationstherapie mit keratinozyten- wachstumfaktor und ein epidermis-wachstumfaktor inhibitor | |
| DE60331827D1 (de) | Zusammensetzungen für die radioimmuntherapie von gehirn-tumoren | |
| CA2726050A1 (en) | Achievement of high therapeutic index through molecular imaging guided targeted drug treatment | |
| WO2003103699A8 (en) | USE OF RAMOPLANIN TO TREAT DISORDERS ASSOCIATED WITH THE TAKING OF ANTIBIOTICS | |
| ATE489994T1 (de) | Zusammensetzungen zur behandlung von luminalen entzündlichen erkrankungen | |
| DE60334289D1 (de) | Dithiolopyrrolon-derivate zur behandlung von proliferativen störungen | |
| MXPA05013975A (es) | Tratamiento de enfermedades asociadas con amiloide y epileptogenesis. | |
| SE0202959D0 (sv) | Peptide-Base passive immunization therapy for treatment of atherosclerosis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |